IQVIA

What IQVIA does

IQVIA Holdings Inc. (NYSE: IQV), founded in 1982 and headquartered in Danbury, Connecticut, is a publicly traded global provider of clinical research services, healthcare intelligence, and advanced analytics to the life sciences industry. It operates through three reporting segments — Technology & Analytics Solutions, R&D Solutions (clinical contract research), and Contract Sales & Medical Solutions — and serves 19 of the top 20 pharmaceutical companies as well as biotech, medical device, consumer health, payer, provider, and government end markets across more than 100 countries, supported by approximately 93,000 employees including 13,000+ technology experts.

The company's core technology asset is the IQVIA Connected Intelligence™ platform, which combines 64+ petabytes of proprietary healthcare data, 1.2B+ non-identified patient records, and coverage of approximately 85% of global pharmaceutical sales. On top of this data layer, IQVIA has built the IQVIA.ai Platform, deploying 192 specialized AI agents across 64 use cases, including the proprietary Med-R1 8B Medical Reasoning LLM, running on NVIDIA infrastructure and marketed under the IQVIA Healthcare-grade AI® designation.

IQVIA's business model is enterprise-services based: long-term contracts with life sciences sponsors generate revenue across clinical trial execution, real-world evidence studies, commercial data and analytics subscriptions, technology licensing, AI platform access, and contract sales force deployment. Sub-brands such as IQVIA Biotech, IQVIA MedTech, and IQVIA Digital address distinct sponsor segments, and a $34.2B R&D backlog provides multi-year forward visibility. Go-to-market is primarily direct enterprise sales, increasingly augmented through channel partnerships with Veeva, Salesforce Agentforce, and StackAdapt.

Name

IQVIA

Legal name

IQVIA Inc.

Website

https://iqvia.com

Company type

Public

Founded year

1982

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

IQVIA (NYSE: IQV) is a publicly traded provider of clinical research services, healthcare data, and AI-driven analytics serving 19 of the top 20 pharmaceutical companies plus biotech, medtech, and consumer health sponsors across 100+ countries.

Ownership category

akta.pro rank

Product category

Clinical Research Services & Healthcare Analytics

NAICS

Software Publishers (51321), Custom Computer Programming Services (541511), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Enterprise AI Data & Knowledge Platforms (Vector Databases, Knowledge Graphs) (HDAEANAH)

akta.pro secondary industries

End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA), Regulatory Readiness & Audit Automation (e.g., EU AI Act, NIST AI RMF, ISO/IEC 42001) (HDAAAMAE), Responsible AI, Security & Privacy Platforms (Safety, Guardrails, PII) (HDAEANAG)

Keywords

• Clinical research services
• Real world evidence
• Healthcare data analytics
• Pharmaceutical commercialization
• Pharmacovigilance solutions

Headquarters

HQ city

Danbury

HQ country

United States

HQ region

North America

Offices12 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Technology & Analytics Solutions (Commercial Solutions): Recurring and transactional revenue from data, analytics, AI platforms (IQVIA.ai, IQVIA Connected Intelligence), Commercialization solutions, and information management products for pharma and MedTech. Q1 2026 segment revenue $1.754B (up 11.6% YoY).
2. Research & Development Solutions (R&D Solutions): Contract research organization (CRO) and clinical trial services revenue, including clinical development, decentralized trials, functional services, central labs, and consulting. Q1 2026 segment revenue $2.397B (up 6.2% YoY) with record R&D backlog of $34.2B.
3. Contract Sales & Medical Solutions: Revenue from contract sales outsourcing (CSO) and medical solutions, including field force deployment, speaker programs, and healthcare professional engagement services.
4. Real World Evidence and Data Licensing: Revenue from licensing of proprietary real-world healthcare data assets (1.2B+ non-identified patient records), evidence generation services, and analytic subscriptions for life sciences clients.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

IQVIA is a publicly traded (NYSE: IQV) global provider of clinical research services, real-world evidence, and healthcare data analytics to the life sciences industry. The company combines contract research organization (CRO) services with proprietary technology platforms (IQVIA.ai, IQVIA Connected Intelligence, SmartSolve, Vigilance Platform) to support pharmaceutical, biotech, and MedTech clients across drug development, commercialization, and compliance. It also operates 64+ petabytes of healthcare data, 1.2B+ non-identified patient records, and 192 deployed AI agents serving 19 of the world's top 20 pharmaceutical companies.

Product overview

IQVIA operates a comprehensive platform-plus-modules architecture centered on its IQVIA Connected Intelligence™ framework, which integrates data, expertise, AI, analytics, and technology across clinical, commercial, and real-world operations. The core IQVIA.ai Platform serves as the unified AI foundation built in collaboration with NVIDIA, supporting AI capabilities like the Medical Reasoning LLM (Med-R1 8B), the IQVIA AI Assistant, and over 192 deployed AI agents across 64 use cases. Layered around this core are specialized product suites including the Site Suite, Patient Engagement Suite, Clinical Trial Financial Suite, Quality Management and Regulatory Suite (with SmartSolve RIM and SmartSolve eQMS), and Safety Suite (with the IQVIA Vigilance Platform). Domain-specific offerings include the IQVIA NLP Platform for unstructured text, AI Patient & HCP Profiling variants for Commercial/Medical Affairs/Healthcare, and the Field Force Agent and Global Market Insights (GMI) Agent for commercial engagement. IQVIA also operates sub-brands including IQVIA MedTech (purpose-built MedTech solutions) and IQVIA Biotech (clinical development for biotech), while the IQVIA OneKey dataset serves as the industry's most comprehensive HCP/HCO reference data layer powering many of these offerings.

Differentiator

Problem solved

Functional benefit

Brands

• IQVIA MedTech: Medical device-focused practice area within IQVIA addressing surgical robotics, speaker programs, and MedTech regulatory affairs
• IQVIA Biotech
• IQVIA Digital
• IQVIA Connected Intelligence
• IQVIA.ai
• Healthcare-grade AI
• IQVIA OneKey
• IQVIA Institute
• SmartSolve
• IQVIA Vigilance Platform
• MediaOS
• IQVIA Field Force Agent
• IQVIA Health System Solutions

Products and services

• IQVIA.ai Platform A unified AI platform designed to help life sciences organizations work more efficiently, make better decisions, and scale AI responsibly across clinical, commercial, and real-world operations, built in collaboration with NVIDIA.
• IQVIA Healthcare-grade AI AI engineered specifically for the life sciences industry to meet higher levels of precision, speed, and trust, developed in collaboration with NVIDIA.
• IQVIA AI Assistant A conversational interface tool providing instant insights from a powerful AI-powered interface for life sciences users.
• IQVIA Field Force Agent An AI-powered assistant that helps life sciences field teams plan and execute high-impact, compliant HCP engagements by delivering real-time insights, built on IQVIA's curated, agent-ready healthcare data including IQVIA OneKey.
• Global Market Insights (GMI) Agent An AI agent that provides a unified view of the global market landscape using agentic AI to answer multi-dimensional questions, analyzing market shifts with real-time HCP sentiment and pipeline analysis.
• IQVIA Medical Reasoning LLM (Med-R1 8B) A medical reasoning large language model built to empower healthcare and life science organizations, enhance decision-making, and ultimately transform patient outcomes.
• IQVIA NLP Platform An advanced Natural Language Processing platform that extracts insights at scale from unstructured text — fast, accurate, and proven — used for medical affairs, social determinants of health, and other healthcare communications.
• IQVIA OneKey The industry's most comprehensive HCP/HCO reference data, serving as the foundation for IQVIA's curated, agent-ready healthcare data enabling smarter segmentation, dynamic targeting, and deeper profiling.
• SmartSolve RIM A Regulatory Information Management (RIM) solution that streamlines global QA/RA processes with AI-enabled QMS for compliance, efficiency, and faster market access.
• SmartSolve eQMS An electronic Quality Management System breaking down quality and compliance silos with integrated software across the full product lifecycle.
• IQVIA Vigilance Platform A pharmacovigilance platform delivering speed, accuracy, and global compliance, powered by human expertise and advanced technology.
• Site Suite Increases transparency, improves communications, and reduces administrative burden of clinical trials from start to finish, including the One Home for Sites platform and Investigator Site Portal.
• Patient Engagement Suite Simplifies trials with a solution that improves operations, elevates experience, and drives better patient outcomes, including eCOA and Interactive Response Technology (IRT).
• Clinical Trial Financial Suite An AI-powered platform unifying budgeting, contracting, forecasting, and payments for streamlined clinical trial financial management, including Grant Plan and Clinical Trial Payments.
• Quality Management and Regulatory Suite Streamlines global QA/RA processes with AI-enabled QMS and RIM for compliance, efficiency, and faster market access.
• Safety Suite Streamlines pharmacovigilance with AI-powered automation, global expertise, and real-time safety insights.
• Real World & Healthcare Data Global real world data exploration covering 1.2B+ non-identified patient records across the product lifecycle, providing critical insights across therapeutic areas.
• Market Access Insights Generates evidence needed to support market access and payer approval for healthcare products.
• IQVIA Patient Experience Platform Delivers personalized, technology-enabled patient experiences to improve satisfaction, adherence, and outcomes.
• IQVIA MedTech A dedicated sub-brand providing purpose-built MedTech expertise, including services for surgical robotics, speaker bureau modernization, and EMC regulatory affairs.
• IQVIA Biotech A clinical division providing full-service clinical development solutions with specialized, dedicated teams for biotech companies.
• IQVIA MediaOS IQVIA Digital's end-to-end platform for healthcare marketers, integrating programmatic advertising capabilities with healthcare-grade audience data and compliance features.
• IQVIA Institute for Human Data Science An IQVIA research division contributing to the advancement of human health globally through timely research, insightful analysis, and scientific expertise.
• IQVIA Asset Maximizer A commercial solution for emerging biopharma designed to maximize asset probability of success in a complex, competitive environment with intelligent connections of insights, technology, and expertise.
• Clinical Research & CRO Services Contract research organization services including early-phase clinical trials, Phase IIb/III trials, decentralized clinical trials, functional services, central labs, and R&D consulting for pharma and biotech clients.
• Contract Sales & Medical Solutions Contract sales outsourcing (CSO) and medical solutions, including field force deployment, speaker programs, and healthcare professional engagement services for pharmaceutical companies.

Quantifiable outcome

• 46% faster clinical trial site identification
• +3 more outcomes

Named customers7 records

Segments9 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability13 records

Feature12 records

Partnerships

Nine partnerships are on record, tiered core, flagship and minor.

• StackAdaptcoreTechnology or Integration · 19 June 2026StackAdapt integration with IQVIA Digital's MediaOS to power healthcare advertising. Enables brands and agencies to activate programmatic campaigns with StackAdapt's DSP directly from MediaOS, including HCP audience creation, pre-built segments, and integrated measurement across CTV, video, display, native, and audio.
• Charles River LaboratoriescoreStrategic or Co-development Partner · 17 June 2026IQVIA is acquiring approximately $145 million worth of European drug discovery assets from Charles River Laboratories as part of Charles River's strategic refocusing, extending IQVIA's R&D capabilities into early-stage discovery.
• WileycoreStrategic or Co-development Partner · 15 June 2026Co-published report "Scientific Discovery & AI: The Science-to-Patient Journey" with IQVIA, drawing on insights from a May 2026 summit with 25+ senior leaders from pharma, academia, health systems, and technology. Identifies five high-potential directions for healthcare AI.
• Kexing BiopharmcoreStrategic or Co-development Partner · 14 May 2026Expanded strategic collaboration announced May 14, 2026 to support Kexing's global multi-product biosimilar development and commercialization program. Combines IQVIA's clinical development, regulatory strategy, advanced analytics, AI-enabled trial tools, and commercialization with Kexing's recombinant protein drugs pipeline.
• Salesforce (and Moderna)coreTechnology or Integration · 28 April 2026IQVIA OneKey HCP/HCO reference data is integrated into Salesforce Agentforce Life Sciences for Moderna's global commercial operations. The integration provides master data management and next-best-action support across the Customer 360 platform.
• Boehringer IngelheimflagshipStrategic or Co-development Partner · 1 January 2026Strategic long-term global commercial data foundation transformation collaboration announced January 2026, leveraging IQVIA's data and analytics platforms to underpin Boehringer's commercial operations worldwide.
• Veeva SystemsflagshipStrategic or Co-development Partner · 1 August 2025Long-term clinical and commercial partnerships announced alongside resolution of all prior disputes (August 2025). Establishes a strategic alignment between the two major life sciences technology providers for joint customer engagements.
• Inflexion (Pharmaspectra)minorStrategic or Co-development Partner · 12 August 2022IQVIA acquired UK-based medical affairs data and analytics provider Pharmaspectra from Inflexion for USD 100 million in August 2022, generating a 25% IRR for Inflexion. The deal brought medical affairs data capabilities in-house.
• NVIDIAflagshipStrategic or Co-development PartnerLong-term strategic collaboration to launch IQVIA Healthcare-grade AI® and IQVIA's agentic AI platform. IQVIA built custom AI agents using NVIDIA technology to enhance workflows and accelerate insights for life sciences. 192 AI agents across 64 use cases serve 19 of the top 20 pharma.

Scale indicators15 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• ICON plc: Global CRO providing clinical research, consulting, and commercialization services. Direct head-to-head competitor to IQVIA's R&D Solutions segment across Phase IIb/III trials and biotech services.
• Labcorp (incl. Covance / Fortrea): Major CRO and central laboratory services provider (Fortrea was spun out in 2023 to focus on clinical development). Competes with IQVIA in clinical trials, central labs, and real-world evidence.
• Charles River Laboratories: Preclinical CRO and discovery services provider, from whom IQVIA is acquiring $145M of European discovery assets. Overlaps with IQVIA's R&D Solutions in early-stage and discovery work.
• Thermo Fisher Scientific (PPD): Owns PPD, one of the largest global CROs after IQVIA. Competes across clinical development, central labs, and real-world evidence, and bundles CRO with life sciences instruments and reagents.
• Parexel International: Large private CRO competing with IQVIA across full-service clinical development, decentralized trials, and biotech/biopharma-focused services. Recently taken private by EQT and GIC.
• Veeva Systems: Life sciences cloud software provider (Vault, CRM) with a clinical and commercial platform that historically competed with IQVIA. Resolution of disputes in 2025 turned Veeva into a partner, but it remains a deeply comparable platform peer.
• Medidata Solutions (Dassault Systèmes): Clinical trial technology platform (Rave EDC, eCOA, IRT) that competes with IQVIA's Site Suite, Patient Engagement Suite, and IRT offerings across pharma R&D technology.
• Syneos Health: Clinical and commercial solutions provider (CRO plus contract sales) — directly comparable to IQVIA's R&D Solutions and Contract Sales & Medical Solutions segments. Recently taken private by Elliott Investment Management.

Broad incumbents

• Oracle Health Sciences (formerly Cerner / Oracle Clinical): Broad incumbent offering clinical trial management, eClinical, real-world evidence, and healthcare data infrastructure. Competes with IQVIA's R&D technology and real-world evidence suites from a larger Oracle platform.

Others

• Salesforce (Life Sciences / Agentforce): Platform partner and adjacent technology ecosystem player; integrates IQVIA OneKey data into Agentforce Life Sciences. Comparable as a life sciences CRM/commercial platform peer, though not a CRO competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/IQVIA_global
• Facebookfacebook.com/IQVIA
• LinkedInlinkedin.com/company/iqvia

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries5 records

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A13 records

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IQVIA